Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium tanshinone IIA sulfonate in non-ST-segment elevation acute coronary syndrome undergoing PCI
ChiCTR-TRC-14005182Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sodium tanshinone IIA sulfonate in acute coronary syndrome (ACS) (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Incidence of major adverse cardiac events. Started Sep 2014; status: recruiting.
02
Drugs
sodium tanshinone IIA sulfonate
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR-TRC-14005182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14005182.